{
  "pdf_file": "Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1:CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.pdf",
  "pdf_analysis": {
    "总页数": 6,
    "有文本的页数": 6,
    "有图片的页数": 2,
    "总图片数": 2,
    "PDF类型": "混合PDF"
  },
  "processing_time": "20251214_142913",
  "text_length": 57248,
  "results_count": 2,
  "results": {
    "prompt1_result": "['title':'Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab']",
    "prompt2_result": "```json\n[ {\n  \"1\": \"1\",\n  \"2\": \"2\",\n  \"3\": \"1\",\n  \"4\": \"2\",\n  \"5\": \"2\",\n  \"6\": \"1\",\n  \"7\": \"2\",\n  \"8\": \"1\",\n  \"9\": \"2\",\n  \"10\": \"2\",\n  \"11\": \"2\",\n  \"12\": \"2\",\n  \"13\": \"2\"\n}]\n```"
  }
}